An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)
Latest Information Update: 23 Mar 2023
Price :
$35 *
At a glance
- Drugs Toripalimab (Primary) ; YH 001 (Primary)
- Indications Liver cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eucure Biopharma
- 17 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment as per Sponsor decision.
- 15 Nov 2022 Planned End Date changed from 1 Jun 2023 to 1 Mar 2025.
- 15 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.